###### Key messages

-   **What is the key question?**

-   Several studies have suggested that airborne transmission of *Pseudomonas aeruginosa* among patients with cystic fibrosis (CF) is feasible; however, it is unclear how far cough generated aerosols travel or how long they remain viable in the airborne phase.

-   **What is the bottom line?**

-   Using two validated cough aerosol sampling systems to measure the viability of *P aeruginosa* in droplet nuclei we demonstrate that patients with CF produce cough aerosols containing viable organisms that are capable of travelling up to 4 m and persisting in the air for up to 45 min.

-   **Why read on?**

-   Data presented here challenge current CF infection control practices of separating patients by 1--2 m to prevent cross-infection by respiratory bacteria, suggesting a re-examination of current infection control practices within the CF community is needed.

Introduction {#s1}
============

Communicable respiratory infections are an important cause of mortality and morbidity and result in healthcare costs worth billions of dollars.[@R1] [@R2] The person-to-person transmission of respiratory pathogens may occur by three key routes: *contact transmission,* where infectious respiratory secretions spread by direct contact or indirectly through a contaminated intermediate object or person; *droplet transmission,* where large infectious droplets travel directly over short distances from the respiratory tract to deposit onto mucosal surfaces (eg, nasal and conjunctival mucous membranes); and *airborne transmission,* involving dissemination of small droplet nuclei within the respirable size range that remain infectious over time and distance and are inhaled by susceptible individuals.[@R3] Airborne transmission may pose a significant risk for hospital-acquired respiratory infection,[@R4] with evidence that it is an important mode of acquisition for many respiratory infections, including *Mycobacterium tuberculosis* (TB) and *Bordetella pertussi*s.[@R5] [@R6]

Cystic fibrosis (CF) is the most common life-limiting autosomal-recessive disorder in Caucasians with most affected persons dying in their third-to-fourth decade from respiratory failure complicating chronic pulmonary infections.[@R7] *Pseudomonas aeruginosa* is the most common pathogen in CF lung disease, and once infection is established there is an accelerated decline in lung function, quality of life and survival.[@R8] [@R9] While many patients with CF acquire *P aeruginosa* sporadically from the environment, molecular-typing studies show shared strains are common in some CF centres, suggesting person-to-person transmission may also be occurring.[@R10] [@R11] In Australia, *P aeruginosa* strains AUST-01 and AUST-02 are responsible for 40% of chronic infections[@R11] and are associated with worse clinical outcomes and increased treatment requirements.[@R11] [@R12] The mechanisms of cross-infection in CF are unknown. However, despite CF centres implementing contact and droplet transmission control measures, *P aeruginosa* cross-infection continues[@R11] [@R13] [@R14] and is only interrupted by implementing strict patient segregation policies.[@R15] [@R16]

It seems that a plausible mechanism of transmission between patients is the airborne route. Indeed, patients with CF infected with *P aeruginosa* produce droplet nuclei containing viable bacteria.[@R17] Furthermore, studies using air sampling in CF clinical settings have demonstrated viable *P aeruginosa* after physiotherapy and in corridors outside inpatient cubicle rooms housing patients with shared strain *P aeruginosa* infection.[@R18] [@R19] Others have also suggested that airborne transmission is feasible, with shared and mucoid *P aeruginosa* strains having a survival advantage.[@R20] [@R21] However, methods used in previous studies were unable to demonstrate how long viable bacteria were present in aerosols or how far they could travel from the original source. We therefore sought to enhance understanding of *P aeruginosa* aerosol production in CF in order to (i) determine the duration and distance of viable cough aerosols, (ii) identify the factors influencing pathogen viability and to (iii) understand the effects of room ventilation on controlling the duration of viable airborne *P aeruginosa*.

Methods {#s2}
=======

Subjects {#s2a}
--------

Patients with CF (n=19) aged \>12 years old and chronically infected with *P aeruginosa* were recruited from the Royal Children\'s Hospital (RCH) and The Prince Charles Hospital (TPCH), Brisbane, Australia. Exclusion criteria included recent pneumothorax, haemoptysis and pregnancy. Healthy, non-smoking controls (n=10) were recruited from hospital staff and their families. Further details are provided in the online supplementary methods. The RCH (HREC/11/QRCH/44), The University of Queensland (2012000615) and the Queensland University of Technology Human Research Ethics Committees (1100000618) approved the study and participants (or their guardians) provided their written, informed consent.

Clinical measurements {#s2b}
---------------------

Subjects attended two study days separated by a mean (SD) 7.5 (4.7) days (range 2--21). A sputum sample was collected from each patient with CF on the day of testing. Cough manoeuvres were supervised by a healthcare professional and emergency equipment was available.

Forced expiratory volume in one-second (FEV~1~) and forced vital capacity (FVC) were measured on all subjects according to ATS/ERS guidelines.[@R22] Respiratory muscle strength was measured by maximum inspiratory (MIP) and maximum expiratory (MEP) mouth pressures using a Micro Medical Respiratory Pressure Meter at TPCH. Weight, height, age, sex and clinical status (exacerbation or clinically stable) were recorded.

Determining the distance viable cough aerosols travel {#s2c}
-----------------------------------------------------

A 'Distance Rig' (see online supplementary methods) permitted measurement of cough aerosols in a particle-free environment at distances up to 4 m from the subject (see online [supplementary figure](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S1).[@R23] An Andersen Impactor (28.3 L/min) captured and measured viable cough aerosol particles,[@R17] and a Lasair II-110 optical particle counter (OPC) measured real-time particle concentrations and verified the absence of room air aerosol contamination in the Distance Rig. Andersen Impactor and OPC samples were collected through a common circular isokinetic inlet.

Subjects sat with their head in the Rig breathing high-efficiency particulate air (HEPA)-filtered air for 2 min to purge residual room air from their lungs before coughing as frequently and strongly as was comfortable for 5 min. The Andersen Impactor sampled continuously during the voluntary cough phase. Cough numbers were recorded manually. Cough aerosols were collected at 1, 2 and 4 m (order randomised) from each subject, who performed duplicate cough manoeuvres at each distance.

Determining duration of aerosol viability {#s2d}
-----------------------------------------

A Duration Rig (see online supplementary methods) comprised a 0.4 m^3^ airtight stainless steel cylinder (illustrated in online [supplementary figure](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S3) to assess the duration of aerosol particle viability in the airborne phase. The cylinder was rotated at 1.7 rpm so that gravitational settling and inertial impaction of particles was minimised.[@R24] The system was flushed with HEPA-filtered air before sample collection so that cough aerosols were not contaminated by room air aerosols.

Subjects were seated and fitted with a snorkel-style mouthpiece (CareFusion Australia) connected to 10 cm of flexible tubing. A nose clip was attached and subjects breathed filtered air for 2 min, and then coughed as much as was comfortable for 2 min, with cough numbers recorded manually. The Rig was isolated, and the resultant cough aerosols were aged for 5, 15 or 45 min. Suspended particles were collected with an Andersen Impactor at the conclusion of the ageing period. Measurements after 5 and 15 min ageing were performed in duplicate while, for logistic reasons, only one measurement was performed after 45 min ageing.

Microbiology {#s2e}
------------

Cough aerosol cultures were performed with chocolate bacitracin (300 mg/mL) agar using previously described incubation conditions and colony-forming units (CFU) count protocols.[@R17] Quantitative (sputum) and qualitative cultures were performed on respiratory samples using standard techniques. After presumptive screening, *P aeruginosa* isolates were confirmed by duplex real-time (RT) PCR assays.[@R11] *P aeruginosa* isolates were genotyped using enterobacterial repetitive intergenic consensus-PCR and clusters analysed alongside a previously characterised panel of Australian shared *P aeruginosa* strains.[@R11]

Statistical analysis and modelling of airborne *P aeruginosa* {#s2f}
-------------------------------------------------------------

Continuous variables are reported as mean and SD, and binary variables as frequency and percentage. Analyses were performed using χ^2^ test, one-way and mixed-effects analysis of variance with subjects as the random factor, followed by the least significant difference procedure. Repeatability was estimated by intraclass correlation using a two-way mixed effects analysis of variance. CFU data were transformed as log(X+1), and their means and 95% CI were back transformed to the original units for ease of interpretation. We also performed a sensitivity analysis to account for the potential 'stacking' of organisms in the cascade impactor (see online supplementary methods). *P aeruginosa* decay over time was assessed using the Duration Rig data (5, 15 and 45 min). The half-life of airborne *P aeruginosa* was estimated from the slope of the decay curve. A model (see online supplementary methods) estimated the relative effects of ventilation and airborne biological decay on *P aeruginosa* removal in different healthcare settings, including the study site.[@R20] [@R25] Ventilation rates were expressed in the standard units of air changes per hour (ACH), which describe how many times a volume of air equal to the volume of a room enters each hour.

Results {#s3}
=======

Subjects were well matched for age, sex and height, but those with CF had lower weight, body mass index and lung function ([table 1](#THORAXJNL2014205213TB1){ref-type="table"}). All subjects completed the cough manoeuvres safely. Four patients with CF were studied during a pulmonary exacerbation. Within the CF group there was no significant change in spirometry between study days (intraclass correlation coefficient (95% CI) 0.79 (0.48 to 0.92)). Similarly, total CFUs for *P aeruginosa* in cough aerosols, cough counts and log *P aeruginosa* sputum concentration within subjects were highly repeatable (see online [supplementary table](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S1).

###### 

Demographic, clinical and microbiological characteristics of the study subjects at time of initial cough aerosol experiment, according to type of subject\*

  Characteristic                                                     Subjects with cystic fibrosis (N=19)   Healthy control subjects (N=10)   p Value
  ------------------------------------------------------------------ -------------------------------------- --------------------------------- ---------
  Age---years                                                        25.8±9.2                               26.5±8.7                          0.85
  (range)                                                            14.4--43.4                             16.1--41.5                        
  Male sex---no. (%)                                                 10 (52.6)                              4 (40.0)                          0.52
  Weight (kg)                                                        63.0±11.7                              74.5±16.1                         0.04
  Height (cm)                                                        169.6±6.7                              173.3±1.9                         0.30
  Body mass index                                                    21.8±3.1                               24.6±2.9                          0.03
  FEV~1~                                                                                                                                      
   Value (L)                                                         2.03±0.70                              3.80±0.80                         \<0.001
   Percent of predicted value                                        53.9±19.0                              96.1±11.5                         \<0.001
  FVC                                                                                                                                         
   Value (L)                                                         3.23±0.69                              4.68±0.98                         \<0.001
   Percent of predicted value                                        72.9±15.9                              100.2±9.2                         \<0.001
  MIP†                                                                                                                                        
   Value (cmH~2~O)                                                   105.78±27.38                           95.12±19.13                       0.38
   Percent of predicted value                                        116.7±30.6                             108.4±18.1                        0.53
  MEP†                                                                                                                                        
   Value (cmH~2~O)                                                   126.23±31.67                           130.15±28.91                      0.79
   Percent of predicted value                                        108.5±24.0                             112.7±23.3                        0.72
  Number of coughs per minute                                        26.9±18.5                              37.8±23.5                         0.18
  Infection − no. (%)                                                                                                                         
  *Pseudomonas aeruginosa*                                           19 (100.0)                             --                                --
   Mucoid *P aeruginosa*                                             15 (78.9)                              --                                --
   Non-mucoid *P aeruginosa*                                         18 (94.7)                              --                                --
  *Staphylococcus aureus*                                            5 (26.3)                               --                                --
  *Stenotrophomonas maltophilia*                                     2 (10.5)                               --                                --
  *Trichosporon/Arxula* spp*.*                                       3 (15.8)                               --                                --
  *Aspergillus* spp.                                                 3 (15.8)                               --                                --
  *Scedosporium* spp.                                                2 (10.5)                               --                                --
  *Candida* spp.                                                     1 (5.7)                                --                                --
  Sputum *P aeruginosa* concentration−colony-forming units per mL‡   1.37×10^8^ (2.16×10^7^--1.06×10^9^)    --                                --

\*Values are means±SD unless otherwise indicated.

†Maximal static inspiratory and expiratory mouth pressures (MIPS and MEPS) were calculated for only 12/19 test subjects and 7/10 control subjects.

‡Data are presented as median values (IQR). Only 18/19 test subjects were able to expectorate sputum on the initial experimental day.

Eighteen patients with CF produced sputum and one provided a cough swab ([table 1](#THORAXJNL2014205213TB1){ref-type="table"}), with *P aeruginosa* isolated from all and 15/19 (79%) yielding at least one mucoid isolate. Sputum *P aeruginosa* concentrations ranged from 4.0×10^6^ to 4.2×10^9 ^CFU/mL. Genotypic analysis revealed 12 strains shared commonly within the Australian CF community[@R11]; AUST-01 (1), AUST-02 (7), AUST-06 (2), AUST-07 (1) and AUST-19 (1), and seven unique strains. Five patients harboured two different strains. Other organisms cultured are detailed in [table 1](#THORAXJNL2014205213TB1){ref-type="table"}.

*P aeruginosa* was cultured in cough aerosols from all patients with CF, but not from any controls. Viable *P aeruginosa* was isolated at 4 m from 17/18 (94%) and at all distances from 16/18 (89%) of the CF group ([figure 1](#THORAXJNL2014205213F1){ref-type="fig"}). Aerosolised *P aeruginosa* remained viable for 45 min from 14/18 (78%) subjects in the duration experiments ([figure 2](#THORAXJNL2014205213F2){ref-type="fig"}). Most viable *P aeruginosa* isolates were cultured from particles \<3.3 μm ([table 2](#THORAXJNL2014205213TB2){ref-type="table"}) and the strains cultured from cough aerosols were genotypically indistinguishable from those isolated in respiratory samples from the same patient. *Stenotrophomonas maltophilia* and *Arxula adeninivorans* were also cultured in cough aerosols and sputum from two patients. No other respiratory pathogens cultured in sputum were isolated from cough aerosols. No *P aeruginosa* or other microbes identified in cough aerosols were isolated from surface swabs or blank aerosol samples taken during the studies (see online supplementary methods).

###### 

Colony-forming unit (CFU) counts of *Pseudomonas aeruginosa* isolated from the cough aerosol cultures of subjects with cystic fibrosis (CFUs in total aerosol, and in large and small particle fractions are shown)\*

  Distance          1 m                    2 m                     4 m                    ANOVA p value†
  ----------------- ---------------------- ----------------------- ---------------------- ----------------
  Total‡            52.6 (40.9--67.6)^a^   37.3 (28.9--48.0)^a^    24.8 (19.2--32.0)^b^   0.001
  Large fraction§   27.4 (21.4--34.9)^a^   19.9 (15.5--25.5)^a^    12.6 (9.7--16.2)^b^    \<0.001
  Small fraction¶   27.6 (21.2--35.9)^a^   19.6 (15.0--25.5)^ab^   14.3 (10.9--18.7)^b^   0.005
                                                                                          
  **Duration**      **5 min**              **15 min**              **45 min**             
                                                                                          
  Total‡            14.6 (11.0--19.2)^a^   11.9 (8.9--15.7)^a^     7.7 (5.4--11.0)^b^     0.046
  Large fraction§   4.2 (3.1--5.5)^a^      3.9 (2.9--5.2)^a^       2.3 (1.5--3.4)^a^      0.074
  Small fraction¶   11.9 (9.1--15.6)^a^    9.0 (6.7--11.8)^ab^     6.2 (4.3--8.8)^b^      0.031

\*Values are means (95% CI). Within sets and rows, a different superscript letter (^a^ or ^b^) denotes a significant difference (p\<0.05) between other distances or durations.

†ANOVA for trend across distance or duration.

‡Total CFU counts represent the *P aeruginosa* CFUs isolated from all six Andersen Impactor stages (aerosol particles sizes 0.65 to \>7.0 µm).

§Large particle fraction CFU counts represent the *P aeruginosa* CFUs isolated from stages 1, 2 and 3 (aerosol particle sizes \>7, 4.7--7.0 and 3.3--4.7 µm, respectively) of the Andersen Impactor.

¶Small particle fraction CFU counts represent the *P aeruginosa* CFUs isolated from stages 4, 5 and 6 (aerosol particle sizes 2.1--3.3, 1.1--2.1 and 0.65--1.1 µm, respectively) of the Andersen Impactor.

![Log~10~ combined total colony-forming unit counts of *Pseudomonas aeruginosa* isolated at 1, 2 and 4 m from the Distance Rig cough aerosol cultures of subjects with cystic fibrosis.](thoraxjnl-2014-205213f01){#THORAXJNL2014205213F1}

![Log~10~ combined total colony-forming unit counts of *Pseudomonas aeruginosa* isolated after 5, 15 and 45 min from the Duration Rig cough aerosol cultures of subjects with cystic fibrosis.](thoraxjnl-2014-205213f02){#THORAXJNL2014205213F2}

Marked intersubject heterogeneity was seen in the total numbers of viable *P aeruginosa* cultured from cough aerosols ([figure 1](#THORAXJNL2014205213F1){ref-type="fig"}; see online [supplementary table](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S2). Measured *P aeruginosa* CFUs decreased with the distance the aerosol travelled and with the ageing time; CFUs were significantly higher at 1 m than 4 m, and at 5 min than 45 min ([table 2](#THORAXJNL2014205213TB2){ref-type="table"}). CFUs remained significantly higher for both distance and duration when corrected for the effects of stacking (see online [supplementary table](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S3). In both distance and duration studies, strong correlations were seen between total, small and large fraction cough aerosols (r=0.90--1.0). A positive correlation was found between sputum and aerosol *P aeruginosa* CFUs in both distance (r=0.73--0.78) and duration (r=0.85--0.90; see online [supplementary table](http://thorax.bmj.com/lookup/suppl/doi:10.1136/thoraxjnl-2014-205213/-/DC1) S4) studies, although there was no significant correlation found between clinical or demographic variables and cough aerosols produced in either study. Correlations for these variables were unchanged when measured CFUs were corrected for stacking (see online supplementary table S5)

The influences of biological decay and room ventilation on *P aeruginosa* in cough aerosols were modelled (see online supplementary methods). Environmental conditions in the Duration Rig were similar to those in the air-conditioned clinical setting. The number of viable *P aeruginosa* in cough aerosol followed an exponential decay with a half-life of 50 min (95% CI 30 to 151 min). Room ventilation removed additional viable *P aeruginosa* and became the dominant mechanism of removal at ventilation rates above the biological decay rate of the cough aerosol (ie, approximately 0.85 ACH). [Figure 3](#THORAXJNL2014205213F3){ref-type="fig"} shows the time taken to achieve 10, 50, 90, 99 and 99.9% reductions in airborne *P aeruginosa* following the departure of a source patient, including the combined effects of biological decay and room ventilation. At 2 ACH, 90% of viable airborne *P aeruginosa* are removed in approximately 49 min (95% CI 41 to 61 min), decreasing as ventilation rate increases to approximately 24 min (95% CI 22 to 26 min) at 5 ACH and to 13 min (95% CI 12 to 13 min) at 10 ACH.

![Time taken to achieve 10, 50, 90, 99 and 99.9% reductions in airborne *Pseudomonas aeruginosa* due to the combined effects of biological decay and room ventilation.](thoraxjnl-2014-205213f03){#THORAXJNL2014205213F3}

Discussion {#s4}
==========

Cross-infection between patients with CF can adversely affect health outcomes, but how this occurs and the transmission pathways involved remain uncertain. We have shown that patients with CF produce aerosols containing viable *P aeruginosa* during coughing. Particles within the respirable range persist over distance and time, providing a potential vehicle for airborne transmission between patients. Marked intersubject heterogeneity of aerosol production was observed, suggesting that some patients may be 'super-spreaders' of *P aeruginosa.* Finally, sputum *P aeruginosa* concentration was a strong predictor of viable cough aerosol concentrations.

Evidence of highly prevalent shared *P aeruginosa* strains within CF populations suggests person-to-person transmission.[@R10] [@R11] [@R26] Using air sampling equipment both in the clinical setting, viable *P aeruginosa* have been demonstrated close to patients with shared strain *P aeruginosa* infection.[@R18] [@R19] The clinical significance of these findings was unclear and led us to study the size distribution of cough aerosols, and we have previously demonstrated *P aeruginosa* can be present in aerosols generated by coughing.[@R17] However, we were unable to determine how far these aerosols travelled or the duration they remained viable in the airborne phase. An *in vitro* aerosol production system has demonstrated that artificially produced *P aeruginosa* aerosols can survive up to 45 min and that survival was greater with mucoid *P aeruginosa.*[@R20] [@R21] The present study confirms aerosols produced during coughing by infected patients contain viable *P aeruginosa* that travel up to 4 m and stay suspended for at least 45 min. These data add to existing evidence that airborne transmission is likely to play a role in patients with CF acquiring *P aeruginosa*.

Our study demonstrates that droplet nuclei, generated by coughing, and containing viable *P aeruginosa*, are small enough to stay airborne for extended periods and over long distances. They are also well within the size range to deposit within the tracheobronchial tree following inhalation.[@R27] Such droplets can be efficiently disseminated to locations far from their origin by mechanical room air ventilation systems, which often recirculate up to 80--90% of air used for heating or cooling. The role of room ventilation as a potentiator of airborne transmission of microbes such as *M tuberculosis*, measles, SARS-coronavirus and varicella zoster is well documented.[@R4]

Published guidelines for ventilation in hospitals suggest that 2 ACH of fresh (ie, non-recirculated) air are required for clinic rooms and general wards, 3 ACH are recommended for procedure rooms and 12 ACH are needed for isolation rooms.[@R28] [@R29] We have previously published results of measuring ACH in various clinical locations within TPCH and found that these meet or exceed recommended levels in most cases, with an extreme example of almost 24 ACH in an isolation room in the emergency department.[@R25] However, the data from the present study suggest that a clinic room with the recommended two ACH may require almost an hour after a patient harbouring *P aeruginosa* leaves the room before 90% of the viable bacteria are removed from the air (see online supplementary methods). These data have substantial implications for CF infection control practices. Our modelling suggests that increasing room ventilation provides some benefit; however, the time required to remove 90% of potentially infectious aerosols still exceeds 10 min despite substantial increases in ACH ([figure 3](#THORAXJNL2014205213F3){ref-type="fig"}). A new paradigm may be needed, such as employing within CF centres advanced ventilation and ultraviolet germicidal irradiation (UVGI) techniques to achieve infection control, as is done for TB clinics.[@R30] [@R31]

This study has several important limitations. The infectious inoculum required to establish *P aeruginosa* infection in CF is unknown and may vary between patients.[@R20] Thus, it is impossible to estimate to what extent viable aerosols of *P aeruginosa* need to be removed to eliminate the risk of infection in susceptible patients. In many CF clinical settings, contact and droplet infection control measures have been implemented, but reduced rates of shared *P aeruginosa* strain infections have been reported only in centres employing strict cohort segregation based upon molecular typing surveillance.[@R15] It therefore remains uncertain whether these simpler measures are sufficient, and if preventing airborne transmission should also be considered when strict segregation of large patient cohorts attending major CF centres is not always feasible.[@R14]

Our study included a small number of older patients with chronic *P aeruginosa* infection and moderately severe airflow obstruction. Thus, we cannot comment on viable aerosol production during coughing by younger or healthier patients or in those with transient *P aeruginosa* infections. In addition, we used culture media that selected for aerobic gram-negative bacteria and we cannot provide data on other microbes, including *Staphylococcus aureus,* non-tuberculous mycobacteria or respiratory viruses.[@R14] [@R32] [@R33] Future studies using other selective media to determine the viability of other microorganisms in cough aerosols are now required. Due to bactericidal effects, it is also possible that the bacitracin used in the culture media reduced the recovery of some *P aeruginosa* organisms. Finally, modelling data assume that the room air is perfectly mixed, which is rarely the case. As such, our estimates of the time taken to remove viable *P aeruginosa* from a clinic room may be overestimates or underestimates of real-world scenarios (see online supplementary methods).

The present study uses bacterial infection in patients with CF to demonstrate the potential for aerosol transmission in healthcare settings and adds to studies suggesting similar mechanisms for *M tuberculosis* and for *B pertussis* in non-human primate models.[@R5] [@R6] Our results provide further evidence, which challenges the dogma that CF bacterial pathogens within droplet nuclei have limited survival in air. Indeed, airborne transmission may be a more important mechanism of cross-infection within the CF community than previously considered to be the case. Furthermore, our data add to the controversy generated by the current USA CF Foundation guidelines that only one person with CF attend a CF Foundation-sponsored or CF Centre-sponsored event[@R34]; recommendations strongly opposed by some adults with CF.[@R35]

In summary, this study indicates that when patients with CF harbouring *P aeruginosa* cough, they produce an aerosol containing viable organisms capable of travelling 4 m and persisting in the air for 45 min. These data challenge current CF infection control guidelines that remain in place in many parts of the world, including the separation of patients by 1--2 m to prevent cross-infection by respiratory bacteria.[@R13] [@R36] Consequently, further studies on transmission are needed and infection control practices recommended currently for the CF community may need to be re-evaluated.
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